Market Cap: $1.08B
AI
Amphastar Pharmaceuticals, Inc.
AMPH
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.08B
Amphastar Pharmaceuticals (Ticker: AMPH) focuses on significant product launches and revenue growth strategies, aiming to enhance its market presence in the competitive healthcare landscape. The compa…
Amphastar Pharmaceuticals Strengthens Position in Biopharmaceuticals Amid Industry Challenges Amphastar Pharmaceuticals, a key player in the biopharmaceutical sector, focuses on the development and co…
Amphastar Pharmaceuticals Reports Strong Q4 Performance Driven by Strategic Initiatives Amphastar Pharmaceuticals, Inc. establishes a robust position in the pharmaceutical sector with its recently rep…
Amphastar Pharmaceuticals Prepares for Critical Earnings Report Amid Competitive Landscape Amphastar Pharmaceuticals is gearing up to release its quarterly earnings report on February 26, 2026, a key…
Earnings Reveal Growth Dynamics at Amphastar Pharmaceuticals Amphastar Pharmaceuticals has announced its Q4 earnings report for the end of February 2026, revealing robust financial performance that po…
Amphastar Pharmaceuticals’ Promising Q4 Performance Sets Stage for Future Growth Amphastar Pharmaceuticals, Inc. recently reports its Q4 earnings for the fiscal year ending February 26, 2026, showcasi…
Amphastar Pharmaceuticals: Importance of Earnings Reports in Shaping Market Sentiment Amphastar Pharmaceuticals operates within the dynamic landscape of the pharmaceutical industry, where earnings rep…
Amphastar Pharmaceuticals: Advancing Innovation in Biopharmaceuticals Amphastar Pharmaceuticals, a key player in the biopharmaceutical industry, is focused on expanding its portfolio of injectable and…
Amphastar Pharmaceuticals: Innovation in the Pharmaceutical Landscape Amphastar Pharmaceuticals, a key player in the pharmaceutical industry, continues to focus on innovative solutions that address cr…
Proposed Tariff Exclusion for Imported Generic Drugs: A Game Changer for Amphastar Pharmaceuticals The Trump administration is reportedly considering a significant policy change that would exclude imp…
Trump Administration Considers Tariff Exclusion for Imported Generic Drugs, Impacting Pharmaceutical Landscape The Trump administration is evaluating a significant policy change that could exempt impo…
Pharmaceutical Policy Shift: A New Era for Generic Drugs in the U.S. The Trump administration is contemplating a significant policy change that could reshape the landscape of the pharmaceutical indust…
Amphastar Pharmaceuticals Expands Injectable Iron Supplement Portfolio with FDA Approval Amphastar Pharmaceuticals, Inc. achieves a significant milestone as it receives approval from the U.S. Food and…